Tema Etfs LLC Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Tema Etfs LLC bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 7,962 shares of the medical equipment provider's stock, valued at approximately $712,000.

A number of other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC raised its holdings in Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after acquiring an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC grew its position in shares of Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Lantheus by 2.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after buying an additional 30,891 shares during the period. Finally, Swedbank AB boosted its stake in Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after buying an additional 385,000 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock worth $6,016,046 over the last quarter. Corporate insiders own 1.50% of the company's stock.

Lantheus Trading Down 2.2%

Shares of NASDAQ LNTH traded down $1.70 during midday trading on Wednesday, reaching $75.13. The company's stock had a trading volume of 981,097 shares, compared to its average volume of 985,423. The company has a market cap of $5.20 billion, a price-to-earnings ratio of 12.50 and a beta of 0.23. Lantheus Holdings, Inc. has a one year low of $75.00 and a one year high of $126.89. The company has a 50 day moving average price of $96.20 and a 200 day moving average price of $92.76.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same quarter in the previous year, the firm earned $1.69 earnings per share. The business's revenue was up .8% compared to the same quarter last year. Research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

LNTH has been the subject of several research analyst reports. StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. B. Riley lowered their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, Truist Financial cut their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $132.67.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.